Red Blood Cell Precursor Formulation to Determine Increased Production

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Anemia

In brief

The objective of this study is to measure the change in hemoglobin levels after the administration of an amino acid based, RBC precursor formulation.

Key facts

Study ID

NCT01701531

Run by

Targeted Medical Pharma

People needed

0

Starts

2012-10-01

Expected to finish

2014-05-01

Last updated by the study team

2016-05-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• M/F patients 18 to 75 years old, non-pregnant/lactating
• Male patients with < Hemoglobin of 12.5
• Female Patients with < Hemoglobin of 11
• Diagnosis of mild to moderate anemia by study physician

You may not qualify if…

• Pregnant or unwilling to use adequate birth control for the duration of the study.
• Unwilling or unable to sign informed consent.
• Myocardial infarction within the last 6 months.
• Patients currently taking an erythropoietin medication and unable to discontinue for the duration of the study.
• GI bleed in the last 6 months.
• Inflammatory bowel disease.
• Chronic liver disease.

Where it is running

• Lawrence May, MD, Inc. — Tarzana, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.